Voyager Therapeutics Equity 2024

Voyager Therapeutics Aktienanalyse

What does Voyager Therapeutics do?

Voyager Therapeutics Inc is a biopharmaceutical company specializing in the development of gene therapy products. The company was founded in 2013 in Cambridge, Massachusetts. The main business model of Voyager Therapeutics involves the development, manufacturing, and marketing of gene therapy products. The company specializes in nervous system and ocular therapies and works closely with leading scientists and clinical institutes. Voyager Therapeutics has several business and research divisions: the Parkinson's Disease division, the Huntington's Disease division, and the Amyotrophic Lateral Sclerosis (ALS) division. The Parkinson's Disease division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Parkinson's disease. The products being developed in this division aim to increase the amount of dopamine in the brain to alleviate the symptoms of Parkinson's disease. Parkinson's patients often suffer from symptoms such as tremors, stiffness, and lack of movement. The Huntington's Disease division of Voyager Therapeutics specializes in developing gene therapy products for the treatment of Huntington's disease. This disease is a hereditary condition that leads to the accumulation of toxic proteins in the brain, eventually causing neurological symptoms such as slow thinking and tremors. The ALS division of Voyager Therapeutics focuses on developing gene therapies for the treatment of Amyotrophic Lateral Sclerosis (ALS). ALS is a neurodegenerative disease in which nerve cells in the brain and spinal cord degenerate, leading to muscle weakness and atrophy. Voyager Therapeutics works closely with various institutions and companies to advance its research and development. Key collaboration partners include Sanofi Genzyme, Abbvie, Neurocrine Biosciences, and the University of Massachusetts Medical School. Some of Voyager Therapeutics' key products are currently in clinical trials or in development. The company is working on developing gene therapies for the treatment of Parkinson's disease, Huntington's disease, and ALS. One example of a product developed by Voyager Therapeutics is VY-AADC, a gene therapy for the treatment of Parkinson's disease. It is currently being tested in Phase 2 clinical trials. Another example is VY-HTT01, a gene therapy for the treatment of Huntington's disease. VY-HTT01 is currently in the preclinical development phase and is expected to be tested in clinical trials in the coming years. Overall, Voyager Therapeutics has a promising future in the gene therapy industry. The company has already achieved significant successes and continues to work intensively on developing new therapies to help people with neurological disorders. Voyager Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Voyager Therapeutics's Equity

Voyager Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Voyager Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Voyager Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Voyager Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Voyager Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Voyager Therapeutics stock

What is the equity of Voyager Therapeutics this year?

Voyager Therapeutics has equity of 236.32 M USD this year.

What was the equity of Voyager Therapeutics compared to the previous year?

The equity of Voyager Therapeutics has increased/decreased by 300.54% increased compared to the previous year.

What impact does a high equity have on investors of Voyager Therapeutics?

A high equity is advantageous for investors of Voyager Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Voyager Therapeutics?

A low equity can be a risk for investors of Voyager Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Voyager Therapeutics affect the company?

An increase in equity of Voyager Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Voyager Therapeutics affect the company?

A reduction in equity of Voyager Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Voyager Therapeutics?

Some factors that can affect the equity of Voyager Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Voyager Therapeutics so important for investors?

The equity of Voyager Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Voyager Therapeutics take to change the equity?

To change equity, Voyager Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Voyager Therapeutics pay?

Over the past 12 months, Voyager Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Voyager Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Voyager Therapeutics?

The current dividend yield of Voyager Therapeutics is .

When does Voyager Therapeutics pay dividends?

Voyager Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Voyager Therapeutics?

Voyager Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Voyager Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Voyager Therapeutics located?

Voyager Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Voyager Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Voyager Therapeutics from 7/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/17/2024.

When did Voyager Therapeutics pay the last dividend?

The last dividend was paid out on 7/17/2024.

What was the dividend of Voyager Therapeutics in the year 2023?

In the year 2023, Voyager Therapeutics distributed 0 USD as dividends.

In which currency does Voyager Therapeutics pay out the dividend?

The dividends of Voyager Therapeutics are distributed in USD.